Susquehanna International Group
SCNI

Susquehanna International Group’s Scinai Immunotherapeutics SCNI Stock Holding History

Susquehanna International Group’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,092
Closed -$14.9K – 12863
2023
Q2 		$14.9K Buy
+1,092
New +$18.9K ﹤0.01% 11692
2022
Q3 		– Sell
-111
Closed -$13K – 14011
2022
Q2 		$13K Sell
111
-452
-80% -$62K ﹤0.01% 12459
2022
Q1 		$94K Buy
+563
New +$81.7K ﹤0.01% 11957
2017
Q2 		– Sell
-142
Closed -$83K – 9753
2017
Q1 		$83K Buy
+142
New +$73.1K ﹤0.01% 8464

Other funds holding SCNI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
APC
Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $5.64B AUM
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Susquehanna International Group's SCNI Position: Q3 2023 in Review

Susquehanna International Group sold out of Scinai Immunotherapeutics (SCNI) in Q3 2023, closing a stake of 1,092 shares — an estimated $14.9K sold.

Susquehanna International Group first reported a position in SCNI in Q1 2017 and held it in 4 quarters. The position peaked at $94K in Q1 2022. 9 funds tracked by Wall St. Rank hold SCNI as of Q3 2023.

  • Susquehanna International Group reported no remaining Scinai Immunotherapeutics position as of Q3 2023 after selling out during the quarter.
  • Susquehanna International Group sold 1,092 Scinai Immunotherapeutics shares in Q3 2023, an estimated $14.9K.
  • Susquehanna International Group first reported a position in Scinai Immunotherapeutics in Q1 2017 and held it in 4 quarters.
  • Susquehanna International Group's Scinai Immunotherapeutics position peaked at $94K in Q1 2022.
  • 9 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q3 2023.

Based on Susquehanna International Group's 13F filing for Q3 2023, filed 14 Nov 2023.